KRAS and cancer: Most PDAC patients are resistant to EGFR inhibitors because of KRAS mutations.30 We tested the effect of cetuximab, an anti-EGFR antibody that showed no clinical benefits in KRAS mutant cancers, on the growth of two KRAS mutant PDAC cell lines AsPC-1 and PANC-1.